Update shared on21 Aug 2025
Fair value Decreased 13%The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43.
What's in the News
- Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
- H1 2025 group revenues were below expectations; adjusted EBITDA was broadly in line.
- Evotec joined the NURTuRE-AKI consortium, enhancing its molecular data capabilities for acute kidney injury and supporting precision medicine and targeted therapeutics.
- Shareholders approved amendments to the Articles of Association to allow virtual general meetings and modified the Share Performance Plan 2022.
Valuation Changes
Summary of Valuation Changes for Evotec
- The Consensus Analyst Price Target has significantly fallen from €11.00 to €9.43.
- The Future P/E for Evotec has significantly fallen from 54.54x to 46.80x.
- The Consensus Revenue Growth forecasts for Evotec has fallen slightly from 8.9% per annum to 8.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.